2008
DOI: 10.1007/s12253-008-9032-1
|View full text |Cite
|
Sign up to set email alerts
|

K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma

Abstract: The Ras/Raf/MEK/ERK (MAPK) signal transduction cascade is an important mediator of a number of cellular fates including growth, survival and apoptosis. The aim of this study was to determine the incidence of B-raf, Kirsten-ras (K-ras) and Neuroblastoma-ras (N-ras) gene mutations in esophageal squamous cell carcinoma (ESCC) in the Greek population. DNA was extracted from 30 ESCC and 32 normal esophageal specimens and screened for V600E B-raf, and K-ras/N-ras codon 12 mutations, by PCR-RFLP based analysis. Among… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
30
0

Year Published

2011
2011
2016
2016

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 34 publications
(33 citation statements)
references
References 30 publications
3
30
0
Order By: Relevance
“…Specific anatomic locations included oral mucosa (n=7), esophagus (n=2), larynx (n=2), adenoids/tonsils (n=2), and parotids (n=1) (Aggelopoulou et al, 1999; Blioumi et al, 2014; Bouda et al, 2000; Gorgoulis et al, 1999; Kouvousi, et al, 2013; Lambropoulos et al, 1997; Laskaris et al, 2014; Lyronis I., 2005; Lyronis, et al, 2008; Mammas, et al 2012; Mammas, et al, 2006; Tsimplaki et al, 2014; Vageli, et al, 2007). Only 5 studies included asymptomatic patients (Blioumi, et al, 2014; Bouda, et al, 2000; Lambropoulos, et al, 1997; Lyronis I., 2005; Lyronis, et al, 2008). The remaining studies focused on testing patients with dysplasia, hyperplasia or cancer.…”
Section: Resultsmentioning
confidence: 99%
“…Specific anatomic locations included oral mucosa (n=7), esophagus (n=2), larynx (n=2), adenoids/tonsils (n=2), and parotids (n=1) (Aggelopoulou et al, 1999; Blioumi et al, 2014; Bouda et al, 2000; Gorgoulis et al, 1999; Kouvousi, et al, 2013; Lambropoulos et al, 1997; Laskaris et al, 2014; Lyronis I., 2005; Lyronis, et al, 2008; Mammas, et al 2012; Mammas, et al, 2006; Tsimplaki et al, 2014; Vageli, et al, 2007). Only 5 studies included asymptomatic patients (Blioumi, et al, 2014; Bouda, et al, 2000; Lambropoulos, et al, 1997; Lyronis I., 2005; Lyronis, et al, 2008). The remaining studies focused on testing patients with dysplasia, hyperplasia or cancer.…”
Section: Resultsmentioning
confidence: 99%
“…It has been reported that RAS/RAF mutations are negatively associated with response to cetuximab. Ras gene and Raf gene mutations occur commonly in some tumors and lead to abnormal signaling, but the incidence of Ras and Raf mutation is very low in esophageal carcinoma [27][28][29]. In light of the relatively low frequency of Ras and Raf mutations and overexpression of EGFR, cetuximab would be appropriate as a combined monoclonal antibody for esophageal carcinoma.…”
Section: Discussionmentioning
confidence: 99%
“…The RAS family genes consist of three members, HRAS, KRAS and NRAS located on chromosomes 11, 12 and 1, respectively, encoding a 21 kDa membrane protein (p21), which possesses GTPase activity (5,6). HRAS has been shown to activate phosphatidylinositol 3 kinase (PI3K) more efficiently than KRAS and NRAS.…”
Section: Introductionmentioning
confidence: 99%
“…BRAF is one of the most commonly mutated oncogenes in human cancer. BRAF is a serine/threonine kinase of the RAF family, which consists of three genes, namely ARAF, BRAF and CRAF (5). More than 90% of the reported BRAF mutations occur in its kinase domain regarding a single nucleotide substitution V600E (also referred to as V599E according to the numbering system used) (13).…”
Section: Introductionmentioning
confidence: 99%